Fomepizole as a First-line Treatment of Patients with Methanol Poisoning

author

  • Bruno Mégarbane Department of Medical and Toxicological Intensive Care Medicine, Lariboisière Hospital, INSERM U1144, Paris-Diderot University, Paris, France
Abstract:

Methanol is responsible for a life-threatening poisoning. Fomepizole, a potent alcohol dehydrogenase inhibitor, is an efficient and safe antidote that prevents or reduces toxic methanol metabolism. Although no study has compared its efficacy with ethanol, fomepizole is recommended as a first-line antidote. Treatment should be started as soon as possible, based on history and initial findings including anion gap metabolic acidosis, while awaiting measurement of serum alcohol concentration. Administration is easy (15 mg/ kg-loading dose, either intravenously or orally, regardless of alcohol concentration, followed by intermittent 10 mg/kg-doses every 12 hours until alcohol concentration becomes less than 30 mg/dL). There is no need to monitor fomepizole concentration. If administered early, fomepizole prevents methanol-related visual and neurological injuries. When administered prior to the onset of significant acidosis or organ injury, fomepizole may obviate the need for hemodialysis. When dialysis is indicated, 1 mg/kg/h-continuous infusion should be provided to compensate for its elimination. Its side-effects are rarely serious and with a lower occurrence than ethanol. Fomepizole is contraindicated in case of allergy to pyrazoles. It is both efficacious and safe in the pediatric population, but is not recommended during pregnancy. In conclusion, fomepizole is an effective and safe first-line antidote for methanol poisoning.

Upgrade to premium to download articles

Sign up to access the full text

Already have an account?login

similar resources

fomepizole as a first-line treatment of patients with methanol poisoning

methanol is responsible for a life-threatening poisoning. fomepizole, a potent alcohol dehydrogenase inhibitor, is an efficient and safe antidote that prevents or reduces toxic methanol metabolism. although no study has compared its efficacy with ethanol, fomepizole is recommended as a first-line antidote. treatment should be started as soon as possible, based on history and initial findings in...

full text

Fomepizole for ethylene glycol and methanol poisoning.

n engl j med 360;21 nejm.org may 21, 2009 2216 This Journal feature begins with a case vignette that includes a therapeutic recommendation. A discussion of the clinical problem and the mechanism of benefit of this form of therapy follows. Major clinical studies, the clinical use of this therapy, and potential adverse effects are reviewed. Relevant formal guidelines, if they exist, are presented...

full text

Treatment of patients with ethylene glycol or methanol poisoning: focus on fomepizole

Ethylene glycol (EG) and methanol are responsible for life-threatening poisonings. Fomepizole, a potent alcohol dehydrogenase (ADH) inhibitor, is an efficient and safe antidote that prevents or reduces toxic EG and methanol metabolism. Although no study has compared its efficacy with ethanol, fomepizole is recommended as a first-line antidote. Treatment should be started as soon as possible, ba...

full text

Neurologic Complications of Methanol Poisoning: A Clinicoepidemiological Report from Poisoning Treatment Centers in Tehran, Iran

Background: In this study we sought to investigate clinical findings (with a focus on neurologic effects) and also to analyze outcomes of a series of patients with methanol poisoning admitted to two poisoning treatment centers in Tehran, Iran. Methods: In this prospective cross-sectional study, methanol-poisoned patients admitted to departments of forensic medicine and toxicology of Loghman Hak...

full text

My Resources

Save resource for easier access later

Save to my library Already added to my library

{@ msg_add @}


Journal title

volume 3  issue Supplement 1

pages  3- 3

publication date 2014-05-01

By following a journal you will be notified via email when a new issue of this journal is published.

Hosted on Doprax cloud platform doprax.com

copyright © 2015-2023